17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma
About this trial
This is an interventional treatment trial for AIDS-related Peripheral/Systemic Lymphoma
Eligibility Criteria
Inclusion Criteria: Histologically confirmed advanced epithelial cancer, malignant lymphoma, or sarcoma for which no standard curative therapy exists Brain metastases allowed after definitive radiotherapy Performance status - ECOG 0-2 Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Bilirubin no greater than 1.5 mg/dL SGOT no greater than 2 times normal Creatinine no greater than 1.5 mg/dL Creatinine clearance at least 60 mL/min Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception for at least 1 week before, during, and for at least 2 weeks after study completion No active infection No other serious concurrent condition No prior allergic reaction to egg products At least 4 weeks since prior biologic therapy (regional or systemic) At least 4 weeks since prior chemotherapy See Disease Characteristics At least 4 weeks since prior radiotherapy
Sites / Locations
- University of Pittsburgh
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Schedule B (tanespimycin)
Schedule C (tanespimycin)
Patients receive 17-AAG IV over 1-2 hours twice weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Patients receive 17-AAG IV over 1-2 hours twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.